<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666497</url>
  </required_header>
  <id_info>
    <org_study_id>103 PH GL 2007 CL003</org_study_id>
    <nct_id>NCT00666497</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>A Phase 2, Randomized, Open-Label Study of Azacitidine (Vidaza) vs MGCD0103 vs Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed AML or Intermediate-2 or High-Risk MDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirati Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine how effective azacitidine, MGCD0103, and the
      combination of azacitidine and MGCD0103 are in treating AML or MDS in people over 60 years of
      age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, 3-arm Phase 2 study will compare the safety and efficacy of single-agent
      azacitidine (currently 1 of 3 approved treatments for myelodysplastic syndrome [MDS]) to that
      of single-agent MGCD0103 and to that of combination therapy with MGCD0103 and azacitidine in
      elderly patients with acute myelogenous leukemia (AML) or intermediate-2 (Int-2) or high-risk
      MDS, for whom no standard of care exists. The goal of the study is to determine which of the
      3 treatment arms are worthy of further investigation in a subsequent Phase 3 study of elderly
      subjects with AML or Int-2 or high-risk MDS.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103.
    All Celgene-sponsored trials with MGCD0103 with be closed.
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate as assessed using IWG criteria for AML and MDS</measure>
    <time_frame>After 45, 90, 135, and 180 subjects are enrolled and evaluated for response to treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response; Time to progression; Progression-free survival; RBC transfusion independence; Hematologic improvement; Quality of life; Safety profile; and Pharmacokinetics of azacitidine and MGCD0103</measure>
    <time_frame>After 45, 90, 135, and 180 subjects are enrolled and evaluated for response to treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacitidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGCD0103</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacitidine + MGCD0103</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>75 mg/m2/day for 5 days, subcutaneous (SC) injection, Days 1 - 5 of every 28-day cycle</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGCD0103</intervention_name>
    <description>90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGCD0103</intervention_name>
    <description>90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide written informed consent, and be willing and able to comply with all
             the study procedures

          -  Must be 60 years of age or older

          -  Must have a pathologic confirmation of newly diagnosed (de novo or untreated
             secondary) AML or newly diagnosed Int-2 or high-risk MDS (IPSS classification)
             according to WHO criteria

          -  Must have a Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          -  Must have adequate organ function, including total bilirubin ≤ 1.5 x upper limit of
             normal (ULN); AST &amp; ALT ≤ 2.5 x ULN; and serum creatinine ≤ 2.0 x ULN.

        Exclusion Criteria:

          -  Considered fit for intensive chemotherapy and opt to be treated with intensive
             chemotherapy

          -  Prior transplantation or any prior anticancer therapy (standard or investigational,
             including chemotherapy, treatment with HDAC inhibitors, or combination HDAC and
             azacitidine) administered to treat AML or MDS.

          -  Clinical evidence of central nervous system (CNS) involvement by leukemia

          -  A diagnosis of promyelocytic leukemia

          -  Previous or concurrent malignancy except adequately treated basal cell or squamous
             cell skin cancer; in situ carcinoma of the cervix, or other solid tumor treated
             curatively, and without evidence of recurrence for at least 3 years prior to study
             entry

          -  Active and uncontrolled clinically significant infection

          -  Known positive serology for hepatitis B surface antigen (HBsAg), hepatitis C antibody
             (HCV Ab) or human immunodeficiency virus (HIV)

          -  Less than 4 weeks elapsed since any major surgery

          -  Any prior or active disease that may interfere with the procedures or evaluations to
             be conducted in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Reid, MSc, MBA</last_name>
    <role>Study Director</role>
    <affiliation>MethylGene Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diamond Centre, Leukemia/BMT Program of BC</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bartholomews Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.leukemia-lymphoma.org/hm_lls</url>
    <description>The Leukemia &amp; Lymphoma Society</description>
  </link>
  <link>
    <url>http://www.mds-foundation.org/</url>
    <description>The Myelodysplastic Syndromes Foundation</description>
  </link>
  <link>
    <url>http://www.leukemia-research.org/NETCOMMUNITY/Page.aspx?pid=183&amp;srcid=-2</url>
    <description>Leukemia Research Foundation</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <disposition_first_submitted>April 6, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 22, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 8, 2015</disposition_first_posted>
  <last_update_submitted>April 22, 2015</last_update_submitted>
  <last_update_submitted_qc>April 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>Vidaza</keyword>
  <keyword>MGCD0103</keyword>
  <keyword>Histone deacetylase inhibitor</keyword>
  <keyword>DNA methyltransferase inhibitor</keyword>
  <keyword>Epigenetic Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Mocetinostat</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

